Global electronic clinical outcome assessment (eCOA) solutions provider Kayentis has opened a new subsidiary in Japan to support the growth of clinical trials sector in the Asia-Pacific region.

The new Tokyo-based subsidiary will enable Kayentis to meet the logistical requirements of multi-national clinical trials being carried out in the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It aims to cater to the needs of local clinical research organisations (CROs) by providing digital data collection services with custom geographic capabilities.

The new facility’s proximity will enable local and international sponsor access to Kayentis’ eCOA services for clinical trials in the mid-to-late stage.

Kayentis has been partnering with Japanese CROs since 2017. More than 75% of clinical trial studies conducted by the company include subjects from Asia-Pacific.

The company established a subsidiary in Boston, Massachusetts, US, two years ago.

Kayentis CEO Guillaume Juge said: “The Japanese and the wider Asia-Pacific clinical trials markets are important to us. Kayentis already has customers in the region. We are thrilled to be opening a subsidiary in Tokyo, where we will be able to offer closer support to our customers running trials in Asia.

“This expansion comes amid the release of our eCOA solution, Clin’Form3, available in Japanese. It brings new design improvements that save time during the set-up stages of the study.

“We anticipate that the easier integration of medical device data and reporting enhancements will be of great benefit to clients in this strategic market.”

The Tokyo-based subsidiary is expected to become operational in January 2020.